vaccine

Six-year follow-up from a 16-patient Phase 1 trial of autogene cevumeran shows unprecedented survival rates in one of oncology's deadliest cancers, now entering a global Phase 2 trial.

A first-in-human trial published in Nature shows BioNTech's individualized neoantigen mRNA vaccine produces durable T cell immunity and sustained disease control in aggressive breast cancer.

Harvard's DoriVac platform, built from self-assembling DNA nanostructures, matches mRNA vaccine immune responses while eliminating cold chain requirements, a Nature Biomedical Engineering study shows.

ARMR Sciences begins Phase 1 trials of a vaccine that trains the immune system to intercept fentanyl before it reaches the brain, a preventive approach with no precedent in addiction medicine.

Five-year KEYNOTE-942 trial data show Moderna and Merck's individualized neoantigen mRNA vaccine maintains a 49% reduction in melanoma recurrence or death.